Skip to content

Giuseppe Floresta

Department of Drug and Health Sciences, University of Catania, 95124 Catania, Italy.

2 papers in the library · 30 citations · publishing 2019-2025

Papers

Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands.

International journal of molecular sciences January 23, 2019 Giuseppe Floresta, Maria Dichiara, Davide Gentile et al. 16 citations

Ibogaine, a psychoactive alkaloid, binds strongly to the sigma-2 receptor, which is implicated in neurological disorders such as Alzheimer's disease, schizophrenia, alcohol abuse, and pain. Because ibogaine's serious side effects prevent clinical use, researchers sought ibogaine derivatives with better sigma-2 receptor affinity. They performed a deconstruction of ibogaine's tricyclic moiety and scaffold-hopping of its indole part, using a 3D-QSAR model to predict sigma-2 receptor binding affinities and molecular docking on a homology-modeled sigma-2 receptor to validate top candidates. Pinoline, a carboline derivative, was tested in a radioligand binding assay and showed predicted high micromolar affinity and good selectivity. These results may guide design of simplified ibogaine analogs with improved sigma-2 receptor binding.

Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.

Brain sciences April 22, 2025 Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta et al. 14 citations

Chemsex involves using drugs like synthetic cathinones, GHB/GBL, ketamine, methamphetamine, and others to enhance and prolong sexual experiences. Stimulants increase sexual arousal, performance, and social interactions; MDMA-like drugs foster emotional closeness; GHB/GBL promotes disinhibition, leading to condomless sex with multiple partners; ketamine facilitates receptive anal intercourse or fisting. Polydrug use can cause serotonergic syndrome, seizures, drug interactions, and sympathomimetic overstimulation, along with psychopathological conditions that may lead to misuse of opioids, gabapentinoids, or antipsychotics. Reducing stigma and providing multidisciplinary medical, psychological, and social support are key to managing these challenges.